Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control

Cross-presenting Xcr1(+)CD8α DCs are attractive APCs to target for therapeutic cancer vaccines, as they are able to take up and process antigen from dying tumor cells for their MHCI-restricted presentation to CD8 T cells. To this aim, we developed fusion proteins made of the Xcr1 ligand Xcl1 fused t...

Descripción completa

Detalles Bibliográficos
Autores principales: Botelho, Natalia K., Tschumi, Benjamin O., Hubbell, Jeffrey A., Swartz, Melody A., Donda, Alena, Romero, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399421/
https://www.ncbi.nlm.nih.gov/pubmed/30863405
http://dx.doi.org/10.3389/fimmu.2019.00294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399421/
https://www.ncbi.nlm.nih.gov/pubmed/30863405
http://dx.doi.org/10.3389/fimmu.2019.00294

Ejemplares similares